
CRISPR Therapeutics AG
CRSPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 4, 2026 | Wells Fargo | Yanan Zhu | $70.00(+40%) | $49.99 | StreetInsider |
| Oct 15, 2026 | UBS | $52.00(+4%) | $50.22 | TheFly | |
| Aug 6, 2026 | Goldman Sachs | $55.00(+5%) | $52.22 | TheFly | |
| Jul 8, 2026 | H.C. Wainwright | Mitchell Kapoor | $80.00(+32%) | $60.77 | StreetInsider |
| Jun 12, 2026 | UBS | $80.00(+59%) | $50.23 | StreetInsider | |
| Jun 11, 2026 | Morgan Stanley | Maxwell Skor | $60.00(+21%) | $49.44 | StreetInsider |
| May 13, 2026 | Bernstein | $56.00(+6%) | $52.83 | TheFly | |
| May 11, 2026 | Evercore ISI | $76.00(+37%) | $55.56 | TheFly | |
| Feb 17, 2026 | Morgan Stanley | $33.00(-37%) | $52.25 | TheFly | |
| Feb 14, 2026 | Chardan Capital | Geulah Livshits | $76.00(+43%) | $53.07 | TheFly |
| Feb 13, 2026 | Needham | $82.00(+52%) | $53.89 | TheFly | |
| Feb 13, 2026 | Evercore ISI | $74.00(+38%) | $53.80 | TheFly | |
| Nov 26, 2025 | Chardan Capital | $74.00(+40%) | $52.79 | TheFly | |
| Nov 11, 2025 | RBC Capital | Luca Issi | $50.00(-8%) | $54.58 | StreetInsider |
| Oct 13, 2025 | Wells Fargo | Yanan Zhu | $75.00(+3%) | $73.09 | TheFly |
| Feb 3, 2025 | H.C. Wainwright | Mitchell Kapoor | $65.00(+63%) | $40.00 | TheFly |
| Nov 6, 2024 | Oppenheimer | Jay Olson | $95.00(+92%) | $49.51 | StreetInsider |
| Nov 5, 2024 | Leerink Partners | Rick Bienkowski | $67.00(+33%) | $50.36 | StreetInsider |
| Aug 12, 2024 | Truist Financial | Joon Lee | $100.00(+115%) | $46.55 | TheFly |
| Aug 6, 2024 | Needham | Gil Blum | $84.00(+68%) | $50.11 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Equal Weight | Nov 4, 2026 |
| Citigroup | maintain | Buy | Nov 4, 2026 |
| Needham | maintain | Buy | Nov 3, 2026 |
| Citizens | maintain | Market Outperform | Aug 31, 2026 |
| Needham | maintain | Buy | Aug 31, 2026 |
| Citizens | maintain | Market Outperform | Aug 25, 2026 |
| Citigroup | maintain | Buy | Aug 4, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 8, 2026 |
| Citizens | maintain | Market Outperform | Jul 6, 2026 |
| Bernstein | maintain | Market Perform | May 13, 2026 |
| Citigroup | maintain | Buy | May 6, 2026 |
| Piper Sandler | maintain | Overweight | Mar 17, 2026 |
| Chardan Capital | maintain | Buy | Feb 17, 2026 |
| Needham | maintain | Buy | Feb 13, 2026 |
| TD Cowen | maintain | Hold | Feb 13, 2026 |
| Evercore ISI Group | maintain | Outperform | Feb 13, 2026 |
| Citizens | maintain | Market Outperform | Jan 30, 2026 |
| Citizens | maintain | Market Outperform | Dec 23, 2025 |
| Needham | maintain | Buy | Dec 23, 2025 |
| Chardan Capital | maintain | Buy | Nov 26, 2025 |
| Citigroup | maintain | Buy | Nov 12, 2025 |
| Baird | maintain | Neutral | Nov 11, 2025 |
| RBC Capital | maintain | Sector Perform | Nov 11, 2025 |
| Needham | maintain | Buy | Nov 10, 2025 |
| B of A Securities | maintain | Buy | Oct 17, 2025 |
Earnings History
Next report: Feb 11, 2027 · EPS est. $-1.17| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 2, 2026 | $-1.15 | $-1.04 | $12.7M | $14.8M |
| Aug 3, 2026 | $-0.94 | $-1.19 | $10.2M | $7.4M |
| May 4, 2026 | $-1.28 | $-1.19 | $1.5M | $6.1M |
| Feb 12, 2026 | $-1.37 | $-1.15 | $864.0K | $4.7M |
| Nov 10, 2025 | $-1.17 | $-1.26 | $889.0K | $9.1M |
| Aug 5, 2025 | $-2.40 | $-1.47 | $892.0K | $6.1M |
| May 6, 2025 | $-1.58 | $-1.27 | $865.0K | $6.0M |
| Feb 11, 2025 | $-0.44 | $-1.15 | $35.0M | $8.1M |
News
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposi…
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $1.17 per share a year ago.
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older – – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C – – Phase 1b data for CTX310 in severe hypertri…
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
One of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy. The biotech could make significant clinical progress with this and other medicines over the next five years.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.
CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.
CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.
CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.